Figure 1.
Inhibition of VEGFR2 (KDR) and FGFR3 phosphorylation by BIBF 1000. (A) Cultured marrow stroma cells were exposed to VEGF (50 ng/mL) in the presence of increasing concentrations of BIBF 1000 for 5 minutes. Dose-dependent abrogation of VEGFR2 phosphorylation (top: anti–p-Tyr100 immunoblots, densitometry) and corresponding immunoblots of total VEGFR2 (bottom) are shown. (B) OPM-2 cells known to express a constitutively active FGFR3 mutant were incubated with increasing concentrations of BIBF 1000 for 5 minutes. FGFR3 phosphorylation was inhibited in a dose-dependent manner (top: anti–p-Tyr85 immunoblots, densitometry). Bottom panel shows corresponding immunoblots of total FGFR3.

Inhibition of VEGFR2 (KDR) and FGFR3 phosphorylation by BIBF 1000. (A) Cultured marrow stroma cells were exposed to VEGF (50 ng/mL) in the presence of increasing concentrations of BIBF 1000 for 5 minutes. Dose-dependent abrogation of VEGFR2 phosphorylation (top: anti–p-Tyr100 immunoblots, densitometry) and corresponding immunoblots of total VEGFR2 (bottom) are shown. (B) OPM-2 cells known to express a constitutively active FGFR3 mutant were incubated with increasing concentrations of BIBF 1000 for 5 minutes. FGFR3 phosphorylation was inhibited in a dose-dependent manner (top: anti–p-Tyr85 immunoblots, densitometry). Bottom panel shows corresponding immunoblots of total FGFR3.

Close Modal

or Create an Account

Close Modal
Close Modal